A detailed history of Acadian Asset Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,387 shares of PTGX stock, worth $99,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,387
Holding current value
$99,036
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$33.72 - $47.33 $80,489 - $112,976
2,387 New
2,387 $106,000
Q4 2022

Feb 14, 2023

SELL
$7.36 - $11.17 $942,087 - $1.43 Million
-128,001 Reduced 93.3%
9,199 $100,000
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $1.08 Million - $1.61 Million
137,200 New
137,200 $1.16 Million
Q1 2021

May 11, 2021

SELL
$19.02 - $31.15 $291,937 - $478,121
-15,349 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$18.49 - $25.13 $283,803 - $385,720
15,349 New
15,349 $309,000
Q4 2019

Feb 06, 2020

SELL
$4.69 - $13.45 $736,147 - $2.11 Million
-156,961 Closed
0 $0
Q3 2019

Nov 07, 2019

BUY
$9.41 - $16.56 $1.48 Million - $2.6 Million
156,961 New
156,961 $1.89 Million
Q2 2019

Aug 08, 2019

SELL
$8.98 - $12.96 $2.18 Million - $3.15 Million
-242,862 Closed
0 $0
Q1 2019

May 09, 2019

SELL
$6.5 - $13.77 $86,827 - $183,939
-13,358 Reduced 5.21%
242,862 $3.05 Million
Q4 2018

Feb 07, 2019

BUY
$6.3 - $10.44 $41,050 - $68,027
6,516 Added 2.61%
256,220 $1.73 Million
Q3 2018

Oct 30, 2018

BUY
$6.82 - $11.26 $108,260 - $178,741
15,874 Added 6.79%
249,704 $2.57 Million
Q2 2018

Jul 24, 2018

BUY
$5.99 - $9.1 $1.05 Million - $1.6 Million
175,849 Added 303.29%
233,830 $1.57 Million
Q1 2018

Apr 12, 2018

BUY
$8.46 - $23.08 $410,496 - $1.12 Million
48,522 Added 512.97%
57,981 $498,000
Q4 2017

Jan 18, 2018

BUY
$14.47 - $20.8 $136,871 - $196,747
9,459
9,459 $197,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.04B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.